Anti-PD1 monoclonal antibodies have shown remarkable benefit in GL261 tumor-bearing mice, yet the recent CheckMate trials of anti-PD1 for newly-diagnosed and recurrent GBM patients suggest that there is not a significant clinical benefit relative to or in conjunction with standard-of-care treatment [29,30,31]. The gene discussed is PDCD1; the disease is glioblastoma.